Search Results

You are looking at 1 - 10 of 113 items for :

  • "firocoxib" x
  • Refine by Access: All Content x
Clear All

pet goats by castrating at an older age when compared to production animals. Firocoxib (FIRO) is an NSAID that is a fast-acting cyclooxygenase-2 selective inhibitor. 7 Cyclooxygenase plays a significant role in the production of prostaglandins

Open access
in Journal of the American Veterinary Medical Association

Firocoxib, 3-(cyclopropylmethoxy)-4-(4-(methylsulfonyl)phenyl)-5,5-dimethylfuranone, is a coxib-class NSAID approved for use in horses to control pain and inflammation associated with osteoarthritis. In general, NSAIDs are indiscriminate

Full access
in American Journal of Veterinary Research

while permitting recovery of ischemic-injured equine jejunum. 15 However, an injectable solution of meloxicam suitable for use in horses with colic is not currently available in the United States. Firocoxib is an NSAID that has excellent COX-2

Full access
in American Journal of Veterinary Research

COX-1 isoform inhibition. 10 In dogs, firocoxib has been demonstrated to be 384 times more selective for the canine COX-2 isoform than for the COX-1 isoform. 10 , 11 Firocoxib has US FDA approval in the United States for control of pain and

Open access
in American Journal of Veterinary Research

analgesia. Firocoxib is a COX-1–sparing NSAID oral tablet that is FDA approved for the control of perioperative signs of pain and inflammation associated with orthopedic surgery in dogs. It is also approved for the control of signs of pain and inflammation

Full access
in Journal of the American Veterinary Medical Association

of this drug in cats. Slightly more is known about the pharmacodynamics and pharmacokinetics of firocoxib b and meloxicam. c In vitro analyses have shown that firocoxib is COX-2 selective (COX-1 sparing) in cats, with a half maximal inhibitory

Full access
in American Journal of Veterinary Research

would allow physiologically normal tissue function. Studies conducted to assess the clinical efficacy of firocoxib have revealed a positive effect on orthopedic pain 13,14 comparable to that of nonselective COX inhibitors. 9 Currently, firocoxib is

Full access
in American Journal of Veterinary Research

our knowledge, no studies evaluating the use of coxibs for the control of pain and inflammation in horses with osteoarthritis have been published to date. Firocoxib, a member of the coxib class of NSAIDs, has been determined to selectively inhibit

Full access
in Journal of the American Veterinary Medical Association

), and a purported highly selective COX-1– sparing drug (firocoxib). The primary objective was to investigate activities of COX and LOX in duodenal mucosa of dogs. A second objective was to assess in vivo inhibition of the COX isoenzyme by firocoxib in

Full access
in American Journal of Veterinary Research

Firocoxib was introduced in 2007 for the control of pain and inflammation associated with osteoarthritis in horses. In contrast to phenylbutazone and other nonselective inhibitors of COX enzymes, firocoxib is a highly specific inhibitor of the COX

Full access
in American Journal of Veterinary Research